The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment.

Autor:	Eickhardt-Dalbøge CS; The Regional Department of Clinical Microbiology, University Hospital of Region Zealand, Region Zealand, Denmark.; Department of Hematology, Zealand University Hospital, Region Zealand, Denmark.; Department of Bacteria, Parasites & Fungi, Statens Serum Institut, Copenhagen, Denmark.; Department of Pathology, Harvard Medical School, Harvard University, Boston, MA., Ingham AC; Department of Bacteria, Parasites & Fungi, Statens Serum Institut, Copenhagen, Denmark., Andersen LO; Department of Bacteria, Parasites & Fungi, Statens Serum Institut, Copenhagen, Denmark., Nielsen HV; Department of Bacteria, Parasites & Fungi, Statens Serum Institut, Copenhagen, Denmark., Fuursted K; Department of Bacteria, Parasites & Fungi, Statens Serum Institut, Copenhagen, Denmark., Stensvold CR; Department of Bacteria, Parasites & Fungi, Statens Serum Institut, Copenhagen, Denmark., Larsen MK; Department of Hematology, Zealand University Hospital, Region Zealand, Denmark.; Department of Pathology, Harvard Medical School, Harvard University, Boston, MA., Kjær L; Department of Hematology, Zealand University Hospital, Region Zealand, Denmark., Christensen SF; Department of Hematology, Zealand University Hospital, Region Zealand, Denmark., Knudsen TA; Department of Hematology, Zealand University Hospital, Region Zealand, Denmark., Skov V; Department of Hematology, Zealand University Hospital, Region Zealand, Denmark., Ellervik C; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Pathology, Harvard Medical School, Harvard University, Boston, MA.; Department of Data and Data Support, Region Zealand, Denmark., Olsen LR; Department of Health Technology, Technical University of Denmark, Copenhagen, Denmark., Hasselbalch HC; Department of Hematology, Zealand University Hospital, Region Zealand, Denmark.; Department of Pathology, Harvard Medical School, Harvard University, Boston, MA., Nielsen XC; The Regional Department of Clinical Microbiology, University Hospital of Region Zealand, Region Zealand, Denmark., Christensen JJE; The Regional Department of Clinical Microbiology, University Hospital of Region Zealand, Region Zealand, Denmark.; Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2023 Jul 11; Vol. 7 (13), pp. 3326-3337.
DOI:	10.1182/bloodadvances.2022008555
Abstrakt:	Chronic inflammation is believed to play an important role in the development and disease progression of polycythemia vera (PV). Because an association between gut microbiota, hematopoiesis, and inflammation is well established, we hypothesized that patients with PV have a gut microbiota distinct from healthy control participants (HCs). Recombinant interferon alfa 2 (IFN-α2)-treatment of patients with PV is reportedly disease modifying in terms of normalization of elevated blood cell counts in concert with a reduction in the JAK2V617F allelic burden. Therefore, we hypothesized that patients treated with IFN-α2 might have a composition of the gut microbiota toward normalization. Herein, via amplicon-based next-generation sequencing of the V3 to V4 regions of the 16S ribosomal RNA gene, we report on an abnormal gut microbiota in 102 patients with PV compared with 42 HCs. Patients with PV had a lower alpha diversity and a lower relative abundance of several taxa belonging to Firmicutes (45%) compared with HCs (59%, P <.001). Furthermore, we report the composition of the gut microbiota to differ between the treatment groups (IFN-α2, hydroxyurea, no treatment, and combination therapy with IFN-α2 and ruxolitinib) and the HCs. These observations are highly interesting considering the potential pathogenetic importance of an altered gut microbiota for development of other diseases, including chronic inflammatory diseases. Our observations call for further gut microbiota studies to decipher potential causal associations between treatment and the gut microbiota in PV and related neoplasms. (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu